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Abstract
Predicting bioactivity and physical properties of small molecules is a central challenge in drug
discovery. Deep learning is becoming the method of choice but studies to date focus on mean
accuracy as the main metric. However, to replace costly and mission-critical experiments by
models, a high mean accuracy is not enough: Outliers can derail a discovery campaign, thus
models need reliably predict when it will fail, even when the training data is biased; experiments
are expensive, thus models need to be data-efficient and suggest informative training sets using
active learning. We show that uncertainty quantification and active learning can be achieved by
Bayesian semi-supervised graph convolutional neural networks. The Bayesian approach estimates
uncertainty in a statistically principled way through sampling from the posterior distribution.
Semi-supervised learning disentangles representation learning and regression, keeping uncertainty
estimates accurate in the low data limit and allowing the model to start active learning from a
small initial pool of training data. Our study highlights the promise of Bayesian deep learning for
chemistry.
∗ aal44@cam.ac.uk
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I. INTRODUCTION
Predicting physiological properties and bioactivity from molecular structure – quantita-
tive structure-property relationships (QSPR) – underpins a large class of problems in drug
discovery. Classical QSPR workflows [1] separate descriptor generation – mapping a 2D [2–5]
or 3D molecular structure [6, 7] into a vector of real numbers using some handcrafted rules
– and machine learning method that connects descriptors to property. Pioneering advances
in machine learning such as graph neural networks directly take a molecular graph as input
and infer the optimal structure-to-descriptor map from data [8, 9], outperforming classical
machine learning methodologies with handcrafted descriptors [10].
Nonetheless, graph neural networks are usually developed using frequentist maximum
likelihood inference, with the benchmark being the mean error on a test set. However, if
the goal of QSPR is to replace mission-critical but expensive experiments, a low mean error
is insufficient: the user needs to have an estimate of uncertainty and know when the model
is expected to fail. This is because typically only a small number of top-ranked predictions
are selected to test experimentally, thus outliers can ruin a discovery campaign. Moreover,
cost limits the number of experiments that can be run, thus an approach that judiciously
designs the training set to maximise information gained is needed.
Uncertainty quantification, or domain applicability, has been extensively considered in
the QSPR literature but not in the context of graph neural networks and not in a statis-
tically complete way. Previous works estimate uncertainty of prediction as the distance in
descriptor space between the input molecule and the training set, or training an ensemble
of models and evaluating the variance [11–14]. More recent works consider conformal re-
gression [15, 16], which trains two models, one for the molecular property and one for the
error. However, there are two sources of uncertainty: Epistemic uncertainty arises due to
insufficient data in the region of chemical space that the model is asked to make predictions
on. Aleatoric uncertainty arises due to noise in the measurements themselves (e.g. noisy
biochemical assays) [17]. Distance to the training set and variance within a model ensemble
approximately capture epistemic uncertainty, whilst employing an ancillary model for pre-
diction error approximately captures aleatoric uncertainty. We will show that the Bayesian
statistical framework captures both sources of uncertainty in a unified and statistically prin-
cipled manner.
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Active learning strategies have been considered in the drug discovery literature [18, 19].
However, those pioneering works considered a priori defined molecular descriptors, and es-
timate uncertainty via variance within an ensemble of models. Notwithstanding the short-
comings with incomplete modelling of uncertainty discussed above, employing graph neural
networks in active learning presents unique opportunities and challenges: High model accu-
racy in the big data limit comes at the cost of being data-hungry. As the descriptor is fully
data-driven, the model cannot estimate how “far” a compound is from the test set in the
low-data limit, leading to poor uncertainty estimate and breaking down the active learning
cycle. Low-data drug discovery has been considered in the context of one-shot learning [20]
which estimates distance in chemical space by pulling data from related tasks. Nonetheless,
this approach requires a priori knowledge on which tasks are related. Works on genera-
tive molecular design overcome this problem [21] by starting the active learning cycle with
< 1000 quantitative measurements, which impose a significant upfront experimental cost.
In this paper, we combine Bayesian statistics – a principled framework for uncertainty
estimation – with semi-supervised learning which learns the representation from unlabelled
data. We show that Bayesian semi-supervised graph convolutional neural networks can
robustly estimate uncertainty even in the low data limit and drive an active learning cycle,
and overcome dataset bias in the training set. Further, we demonstrate that the quality of
posterior sampling is directly related to accuracy of the uncertainty estimates. As different
Bayesian inference methods can be mixed and matched with different models, our study
opens up a new dimension in the design space of uncertainty-calibrated QSPR models.
II. METHODS AND DATA
A machine learning method has two independent components: model and inference. The
model is a function with parameters that relate the input to the output. Inference pertains
to the methodology by which the model parameters are inferred from data. In terms of
model, we focus on graph convolutional neural network models that take molecular graphs
as input. In terms of inference, we focus on the Bayesian methodology.
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A. Supervised graph convolutional neural network
Our baseline model is the graph convolutional fingerprint model [9]. The salient idea is
the message passing operation [22], which creates a vector that summarises the local atomic
environment around each atom while respecting invariance with respect to atom relabelling.
A molecule is described by a graph, where the nodes are atoms and the edges are bonds.
Atom i is described by a vector of atomic properties xv, and a bond connecting i and j is
described by bond properties evw. The algorithm is iterative: at step t, each atom has a
hidden state htv, which depends on “messages” m
t
v received from surrounding atoms as well
as ht−1v . The hidden states can be interpreted as descriptors of local atomic environment,
and the messages allow adjacent atoms to comprehend the environment of its neighbours.
Each atom is initialised to its atomic features, h0v = xv, and
mtv =
∑
w∈N (v)
(ht−1w , evw), (1)
and
htv = σ(H
deg(v)
t−1 m
t
v), (2)
where N (v) denotes the set of atoms bonded to atom v, σ(·) is the sigmoid function, HNt
is a learned matrix for each step t and vertex degree N . The algorithm is run T times,
with T being a hyperparameter. In the final step, the output is given by a multilayer neural
network f(·) that takes a weighted average of the hidden states at each step as input return
a prediction,
y = f
(∑
v,t
softmax(Wth
t
v)
)
(3)
where Wt are learned readout matrices, one for each step t.
We use the implementation reported in the repository [23]. In all experiments, we consider
T = 3, hidden layer at each level has 128 units, fingerprint length 256 (i.e. Wt ∈ R128×256),
and f(·) is a two layer neural network with 128 units each and relu units.
B. Semi-supervised graph convolutional neural network
The fully supervised approach learns molecular descriptors directly from data. This is
an advantage if one has a lot of data but a disadvantage in the data-limited settings such
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as active learning applications, where the objective is to design informative experiments
starting from a small pool of initial training data.
The insight behind the semi-supervised approach is that significant amount of chemical
knowledge is contained within the molecular structures themselves, without any associated
molecular properties (i.e. unlabelled data). Thermodynamic stability puts constrains on
what bonds are possible, and tends to put certain bonds near each other, forming persistent
chemical motifs. For example, just by looking at drug molecules, one would immediately
spot ubiquitous motifs such as amide group, benzene rings etc., and some motifs often
occur together as scaffolds [24]. The key assumption is that those persistent chemical motifs
contribute to the molecular property that we want to predict. We can make mathematical
progress by constructing a descriptor akin to Equation (1) - (3). However, the objective is
no longer trying to fit a particular property. Rather, the hidden states htv, which summarises
the atomic environment around atom v within radius t, are constructed such that they are
predictable from the hidden states of the surrounding atoms. Therefore, the model learns a
descriptor that clusters similar environments.
Specifically, we use the semi-supervised approach developed by Ngyen et al. [25], which
builds on the paragraph vector approach in natural language processing [26]. Given a set of
molecular structures M, the hidden states htv maximise the log-likelihood
L =
∑
m∈M
∑
v∈m
T∑
t=1
logP (htv|um), (4)
P (htv|um) =
exp
(
(htv)
Tum
)∑
n∈M exp ((h
t
v)
Tun)
, (5)
where un is the molecular identifier, obtained by maximising Equation (4), with h
t
v defined
by Equation (1)-(2). We can interpret un as a vector that describes the “type” of molecule,
and the objective encourages the hidden states htv to take values such that similar molecules
have similar atomic environments.
After finding parameters that maximise the objective (4), {htv} are then passed to a
neural network, Equation (3). The parameters of the neural network as well as the readout
matricesWt are learned in a supervised manner. Note that this formalism infers descriptors
using unsupervised learning and uses supervised learning to relate descriptors to molecular
properties.
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We use the implementation reported in the Github repository[27] accompanying ref [25].
In all experiments, we consider T = 3, hidden layer at each level has 128 units, fingerprint
length 256 (i.e. Wt ∈ R128×256), and f(·) is a two layer neural network with 128 units each
and relu units.
C. Bayesian deep learning
In Bayesian inference, the aim is to determine the distribution of model parameters that
conforms to the data, the so-called posterior distribution. Let θ be model parameters, xi
the dependent variables and yi the independent variable, such that
yi = F (xi, θ) + ǫi. (6)
where ǫi ∼ N (0, σ2i ) is the measurement noise. Bayes theorem states the posterior dis-
tribution, P (θ|{xi}, {yi}), is related to the likelihood, P ({yi}|θ, {xi}) and the prior P (θ)
via
P (θ|{xi}, {yi}) =
1
Z
P ({yi}|θ, {xi})P (θ), (7)
where Z is a normalising constant. The prediction for an unknown input xˆ is obtained by
averaging over the posterior
〈yˆ〉 =
∫
P (θ|{xi}, {yi})F (xˆ, θ) dθ. (8)
The uncertainty of model predictions can be readily derived from this Bayesian formalism.
There are two types of uncertainties [17]. First, the epistemic uncertainty, is given by the
variance of the prediction with respect to the posterior
var(yˆ) =
∫
P (θ|{xi}, {yi})(〈yˆ〉 − F (xˆ, θ))
2 dθ. (9)
Second, the aleatoric uncertainty, is the intrinsic noise of the measurement σ2i . This aleatoric
noise can depend on the input, σ2i = σ(x)
2, as certain areas of the chemical space can be
intrinsically more variable.
We note that the log posterior is, up to a constant,
− logP (θ|{xi}, {yi}) =
∑
i
(
1
2σ2i
(yi − F (xˆ, θ))
2 +
1
2
log σ2i
)
− logP (θ), (10)
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which is exactly the mean-squared loss if σi is constant, with logP (θ) being the regulariser.
Therefore, maximum likelihood inference is a special case of Bayesian inference.
The Bayesian formalism is easy to state but computationally expensive. The numerical
bottleneck is the numerical evaluation of the high dimensional integrals (8)-(9). A plethora
of approximate numerical methods have been developed in the literature to overcome this
bottleneck. However, there is no free lunch, and methods which approximate the posterior
well are usually computationally expensive. In this paper, we will consider two approximate
methods spanning the cost-accuracy spectrum.
1. Dropout variational inference
Variational inference seeks to approximate the posterior distribution by a distribution
that is much easier to sample from. Refs [17, 28] show that a popular way to regularise
neural networks – dropout – is equivalent to approximate Bayesian inference. The algorithm
is simple: The neural network is forked at the last layer to have two outputs, the predicted
aleatoric uncertainty σ2i and dependent variable yi, and trained to minimise the loss (10).
However, during training, each unit has a probability p of being set to 0.
For a neural network with M units, refs [17, 28] show that the above algorithm is ap-
proximately equal to finding parameters θ = (Θ1,Θ2 · · ·ΘM) that fit the distribution
q(θ) =
M∏
m=1
Θmzm, zm ∼ Bernoulli(p), (11)
to the posterior distribution P (θ|{xi}, {yi}), where Θm is the parameter vector associated
with the mth unit.
Distribution (11), although not the same as the true posterior distribution, is significantly
easier to sample: In the prediction phase, the model is run N times, and akin to the training
phase each unit has probability p of being set to 0. The final prediction and total uncertainty
is taken to be the mean over N different predictions of depending variable and variance,
{yi, (σi)2}Ni=1,
〈y〉 =
1
N
N∑
m=1
ym, var(y) =
1
N
N∑
m=1
(ym − 〈y〉)2 +
1
N
N∑
m=1
(σm)2. (12)
The first term in Equation (12) is the epistemic uncertainty and the second term is the
aleatoric uncertainty.
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In our numerical experiments, dropout is applied to every unit that is trained using
supervised learning, i.e. every unit in the supervised graph convolutional neural network is
subjected to dropout, whereas for the semisupervised case the layers on top of the hidden
states are trained with dropout.
2. Stein Variational Gradient Descent
Rather than fitting a distribution to the posterior, Stein Variational Gradient Descent
(SVGD) [29] directly draws samples from the posterior via gradient descent. Specifically, let
{θ0i }
N
i=1 be parameters randomly and independently initialised in parameter space. We want
to evolve parameters such that, after T steps, {θTi }
N
i=1 are N independent samples drawn
from P (θtj|{xi}, {yi}). Ref [29] shows that the following dynamical system does the trick:
θ
t+1
i = θ
t
i + ηφ(θ
t
i), (13)
where
φ(θ) =
1
N
N∑
j=1
[
k(θtj , θ)∇θtj logP (θ
t
j|{xi}, {yi}) +∇θtjk(θ
t
j, θ)
]
. (14)
and k(·, ·) is a generic kernel function and η is the learning rate. Equations (13)-(14) can
be interpreted as free energy minimisation of an interacting particle system: a “particle”
(parameter vector) is subjected to a “force” φ(θ), which drives particles to regions of low
energy (low loss), whilst forcing the particles apart to maximise entropy. The total uncer-
tainty is evaluated also with Equation (12), except {ym}Nm=1 are predictions from different
model parameters {θi}Ni=1.
The key advantage of Equation (13) - (14) is that it is a well-defined approximation:
Frequentist inference (c.f. Equation (10)) is recovered if N = 1, whereas when N →∞ the
system exactly samples from the posterior. Therefore, for finite N , the algorithm interpo-
lates between frequentist and full Bayesian inference. The computational cost and memory
demands increase with N , and in this paper we use N = 50.
To illustrate the computational demands of Stein Variational Gradient Descent, Figure
1 shows the wall clock time, on a Nvidia P100 GPU, as a function of the number of gradi-
ent updates steps for graph convolution with dropout, semi-supervised with dropout, and
semi-supervised with SVGD on the melting point dataset discussed below. Both SVGD and
8
Stochastic Gradient Descent use back-propagation to optimize the neural network parame-
ters. For models trained using Stochastic Gradient Descent, the computational complexity
of back-propagation at each iteration is O(BM), where B is the number of training samples
at each iteration and M is the number of parameters in the model. The semi-supervised
model has less parameters than the fully supervised model, thus the wall-clock time is less
per iteration. In SVGD, we need to update N Stein particles per iteration, thus wall clock
time per iteration scales as O(BMN).
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FIG. 1. The wall clock time on a Nvidia P100 GPU of graph convolution with dropout, semi-
supervised with dropout, and semi-supervised with Stein Variational Gradient Descent on the
melting point dataset.
3. Architectures and hyperparameters
As the objective of this paper is to demonstrate the types of chemical problems that
Bayesian deep learning can tackle, we adopt common parameters for graph convolutional
neural networks taken from the literature rather than performing extensive hyperparameter
optimisation and neural architecture search. For both supervised and semi-supervised graph
convolutional neural networks, we keep the number of hidden layers the same as the original
implementation in the GitHub repositories cited above. Following the implementations in
the repositories we keep the dimension of the fingerprint twice of nh, the number of neurons in
the hidden layers, and only optimise the nh by a grid search over {32, 64, 128, 256}, choosing
the value of nh with the best averaged 5-fold cross-validation root mean squared error over
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all the datasets. This leads to the architecture of T = 3, N = 50, hidden units = 128 and
two layers.
D. Datasets
We consider a set of common regression benchmarks for physical properties prediction
and bioactivity prediction. The MeltingPoint dataset is a collection of 3,025 melting point
measurements of drug-like molecules used in a benchmark study [30]. The ESOL dataset
is a set of 1,128 measured aqueous solubilities of organic molecules [31], and the FreeSolv
dataset is a set of 643 hydration free energy measurements small molecules in water [32]. The
ESOL and FreeSolv datasets are used in the MoleculeNet benchmark [10]. The CatS dataset
comprises half-maximal inhibitory concentration log IC50 measurements of 595 molecules
against Cathepsin S, taken from the D3R Grand Challenge 3 and 4 [33]. The Malaria
dataset is a set of in vitro half-maximal effective concentration (log EC50) measurement of
13,417 molecules against a sulfide-resistant strain of P. falciparum, the parasite that causes
malaria [34] used in benchmark [9]. The p450 dataset is a dataset of half-maximal effective
concentration measurements of 8,817 molecules against Cytochrome P450 3A4, a key enzyme
for metabolism and clearance of xenobiotics, taken from the PubChem assay AID 1851.
To give the reader a sense of how “hard” the different datasets are, we consider a simple
baseline model of XGBoost [35] on ECFP6 fingerprints [36]. We split the data into 80/10/10
(training/validation/testing). We take MaxDepth = 5, LearningRate = 0.01, and optimise
the number of estimators (nEstimators = [50, 100, 150, 200, 250]) using the validation set.
Table I shows the coefficient of determination R2 and root mean squared error (RMSE).
Judging from the coefficient of determination, the dataset difficulty is (from easiest to hard-
est) FreeSolv < Melting < ESOL < CatS < Malaria < p450.
III. RESULTS
A. Uncertainty quantification
We first consider how well can the model estimate its own uncertainty given the full
dataset, split into training (80%) and test (20 %) sets. The quality of the uncertainty es-
timate is operationalised by asking what is the model accuracy when the most uncertain
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Dataset Number of data points R2 RMSE
FreeSolv 643 0.765 1.90
ESOL 1128 0.704 1.14
CatS 595 0.654 0.367
MeltingPoint 3025 0.725 50.2
p450 8817 0.291 0.996
Malaria 13417 0.499 0.655
TABLE I. The performance of the baseline XGBoost model on the datasets considered in this
paper.
predictions are removed, with uncertainty quantified by the variance computed from Equa-
tion (12). Our baseline method is graph convolution with dropout, which has recently been
implemented in the DeepChem package as a feature [10], although to our knowledge this is
the first study that benchmarks Bayesian graph convolutional neural networks in terms of
uncertainty quantification.
FIG. 2. Bayesian semi-supervised learning accurately predicts molecular properties and uncer-
tainty. The plots show the model accuracy on the test set as a function of confidence percentile.
The inset highlights the fact that predictions which the model are confident about are indeed
accurate.
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Figure 2 shows that semi-supervised learning with Stein Variational Gradient Descent
accurately estimates uncertainty and significantly outperforms the baseline on every dataset.
The plots show how the test set error varies as a function of confidence percentile – i.e. what
is the error if we only consider the top-n % of compounds in the test set ranked by confidence
(note that confidence is inverse of the uncertainty, quantified by Equation (12)); the shaded
region is one standard deviation, estimated by analysing 5 random partitions of the data into
training and test sets. In every case, the error is a decreasing function of model confidence,
thus the model successfully estimates which predictions are likely to be correct and which
predictions are outliers.
Another metric that we can evaluate is the shape of the confidence-error curve. For
ESOL and FreeSolv, the error is a steeply decreasing at the low confidence limit before
plateauing, suggesting that most predictions are accurate but for a few outliers, which the
Bayesian method can identify. The situation is different for MeltingPoint, Malaria and
p450 – the error is slowly decreasing at the low confidence limit before sharply decreasing
when it approaches the 100% confidence percentile limit (see also insets of Figure 2). This
suggests that a few predictions are very accurate, and Bayesian method can pick out those
accurate predictions amid many less accurate ones. We note that our Bayesian model is
well-suited for virtual screening applications, where the challenge is ensuring that the top-
ranked actives picked out by the model are indeed actives, since only a very small proportion
of the compounds ranked will actually be screened experimentally (the ”early recognition
problem”) [37, 38].
A lingering question whether the quality of the uncertainty estimate is due to a set
of good descriptors (obtained via semi-supervised learning) or accuracy of the Bayesian
methodology. Figure 2 also shows that replacing Stein Variational Gradient Descent with
dropout significantly reduces model performance. At the same confidence percentile, Stein
Variational Gradient Descent consistently outperforms dropout. This suggests that the
quality of posterior sampling drastically impacts the quality of uncertainty estimation.
The quality of uncertainty estimates can also be gauged by the correlation between the
predicted uncertainty on test data points and the error that the model incurs. Table II
shows the Spearman correlation coefficient between the predicted variance and model error.
As expected, combining semi-supervised learning with Stein Variational Gradient Descent
leads to method with the highest rank correlation. This result is consistent with Figure 2,
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Dataset
Graph convolution
with Dropout
Semi-supervised
with Dropout
Semi-supervised
with SVGD
FreeSolv 0.531 ± 0.061 0.439 ± 0.093 0.688 ± 0.053
ESOL 0.112 ± 0.035 0.306 ± 0.079 0.553 ± 0.026
CatS 0.049 ± 0.036 0.066 ± 0.044 0.310 ± 0.019
MeltingPoint 0.192 ± 0.016 0.284 ± 0.035 0.337 ± 0.013
p450 0.167 ± 0.015 0.185 ± 0.049 0.213 ± 0.010
Malaria 0.315 ± 0.028 0.317 ± 0.031 0.378 ± 0.019
TABLE II. Combining semi-supervised learning with with SVGD yields uncertainty estimates
that are strongly correlated with actual model error. The table shows the Spearman correlation
coefficient between the variance predicted by the model and the error on test data points.
which shows that semi-supervised learning with Stein Variational Gradient Descent has the
lowest confidence-error curve. Moreover, the rank correlation between predicted uncertainty
and error broadly (although not exactly) follows the “difficulty” of the data (c.f. Table I) –
FreeSolv and ESOL have the highest rank correlation, and p450 has the lowest.
Previous works on domain applicability have focused on either building an auxiliary model
to predict the error [15, 16], or estimating the uncertainty of a prediction via the distance of
the input to the training set [11, 12, 14]. The former models aleatoric uncertainty whereas
the latter approximately captures epistemic uncertainty. Our Bayesian method captures
both sources of uncertainty in a statistically principled manner. However, our model also
provides independent estimates of epistemic and aleatoric uncertainties. As such, we can
ask the question: is knowing epistemic or aleatoric uncertainty alone sufficient to estimate
whether a prediction is accurate?
Figure 3 shows that the confidence-error curve for semi-supervised learning with Stein
Variational Gradient Descent obtained by considering both epistemic and aleatoric uncer-
tainty is below (or matches) that obtained by considering epistemic or aleatoric uncertainty
alone. Considering both sources of uncertainty leads to much more accurate predictions at
the high confidence limit for ESOL and p450. Moreover, there is no consistent trend as to
whether epistemic or aleatoric uncertainty is more important – for ESOL, epistemic uncer-
tainty is a better estimate of error than aleatoric uncertainty, whereas the opposite is true
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FIG. 3. Epistemic uncertainty and aleatoric uncertainty are distinct sources of uncertainty, and a
combination of them is needed to obtain a good estimate of model error. We plot the confidence-
error curve for semi-supervised learning with Stein Variational Gradient Descent where the confi-
dence is estimated from combining epistemic and aleatoric uncertainty, epistemic uncertainty alone,
and aleatoric uncertainty alone.
for p450 and CatS. As such, one cannot overlook epistemic or aleatoric uncertainty a priori,
and our approach of combining both sources of uncertainty leads to an accurate uncertainty
estimate.
B. Overcoming dataset bias
Our Bayesian methodology also overcomes dataset bias, which has be noted in the recent
literature as the leading cause for overly optimistic results on benchmarks [39]. Most ligand-
based benchmarks are biased in the sense that the molecules reported are tightly clustered
around a few important chemical scaffolds, such that when the dataset is randomly split into
training set and test set, the molecules in the test set are structurally very similar to the
training set. Therefore, a model that only memorises the training set will still achieve a high
accuracy on the test set yet cannot generalise to other regions of chemical space. Methods
such as scaffold splitting [10] and attribution [40] attempt to estimate what would be the true
performance of the model if the dataset were not biased. However, bias is fundamental in
chemical data – an ”uniform distribution” in chemical space does not exist because chemical
14
FIG. 4. Dataset bias can be mitigated with Bayesian uncertainty estimation. We consider a toy
problem of predicting computationally calculated logP using Stein Variational Gradient Descent
and semi-supervised learning, with a biased dataset comprising all beta-lactams or a benzodi-
azepines from ChEMBL. (Left) The model performance when the test set is also drawn from beta-
lactams and benzodiazepines. (Middle) The model performance when the test set is all steroids
from ChEMBL. (Right) The distribution of predicted uncertainty for the model applied to steroids
and the model applied to beta-lactams and benzodiazepines.
space does not have a well-defined metric. Regardless of how one preprocesses the dataset or
train the model, model predictions will always be awry for scaffolds that are not represented
in the dataset. As such, rather than “unbiasing” the data, the practical question is whether
the model can estimate whether it is likely to make a correct prediction for an unseen
molecule given a biased training set.
To show that Bayesian uncertainty estimation overcomes dataset bias, we consider a toy
problem where we know the ground truth and deliberately introduce bias: We consider
the problem of predicting octanol-water partition coefficient (logP ) values, and use com-
puted ACD logP values as a surrogate. We construct a dataset comprising all molecules on
ChEMBL with either a beta-lactam or a benzodiazepine scaffold. The dataset is obviously
very biased as it only contains 2 scaffolds. We then train a model using Stein Variational
Gradient Descent with semi-supervised learning, with the standard 8:2 split between train-
ing and test set on the biased dataset. Figure 4 (left) show that model is reasonably accurate
on the biased test set. We now simulate how an user might unwittingly fall foul of dataset
bias – suppose we use the model to predict logP of all molecules with a steroid scaffold on
ChEMBL. Figure 4 (middle) show that the model performance, perhaps unsurprisingly, is
poor. Steroids are not part of the training set, thus the model cannot predict its physio-
chemical properties. Bayesian uncertainty estimation provides a way out of this quandary –
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Figure 4 (right) shows that the estimated uncertainty of logP prediction on steroids is sig-
nificantly greater than logP prediction on the test set of beta-lactams or a benzodiazepines.
In other words, the model can inform the user when it is inaccurate, thus mitigating the
impact of dataset bias.
C. Low data active learning
Having considered the quality of the uncertainty estimates in the data-abundant limit,
our next question is whether we can estimate uncertainty in the low data limit and drive
an active learning cycle. We consider the objective of obtaining a low model error with a
small training set. The model is first trained from a small initial pool of data (25 % of
the full training set, picked randomly), the model then selects a batch of molecules (2.5%
of the full training set) that has the largest epistemic uncertainty to put into the training
set, and then the model is retrained to suggest other additions, and the cycle continues.
The test set is always 20% of the full dataset, held out at the beginning of the experiment.
We note that other acquisition functions have been suggested in the literature [41], and the
objective function is problem-dependent [18, 19]. Nonetheless, the goal of our experiment
is to evaluate the quality of uncertainty estimate, thus we focus on a simple objective and
acquisition functions. Further, as active learning requires constant retraining of the model,
and Stein Variational Gradient Descent is significantly more computationally intensive than
dropout, we will only consider dropout variational inference.
Figure 5 shows that semi-supervised learning significantly outperforms full supervised
learning in the low data limit. The mean learning curves and error bars are obtained by
analysing 20 active learning runs starting from random dataset splits. Moreover, in the case
of full supervised learning, active learning is unable to deliver a better learning curve than
random sampling, whereas for semi-supervised learning there is a sizeable gap between the
learning curves of random sampling and active learning. This is because the full supervised
method generates molecular descriptors directly from data. Therefore, in the low data limit,
it is unable to learn descriptors that describe the structure of chemical space and chemical
similarity between compounds, thus cannot generate meaningful uncertainty estimates to
drive active learning.
The importance of choosing diverse compounds in the initial screen has been discussed
16
FIG. 5. Semi-supervised learning significantly outperforms full supervised learning in active learn-
ing. The model starts with 25 % of the full training set, selected randomly, and at each iteration
2.5% of the full training set is added to the training set. The molecules added are picked randomly
(random sampling) or picked because they have the largest predicted epistemic uncertainty (active
learning). The curves show the mean model error and standard error of the mean, averaged over
20 active learning runs starting from random dataset splits, as a function of iteration. The insets
focus on the performance of semi-supervised learning with SVGD.
extensively in the literature [42–44], and the performance of our active learning method also
depends on the chemical diversity in the initial screen. Figure 6 shows that active learning
does not outperform random sampling when the initial training set biased and contain only
a small number of scaffolds. We model scaffold bias by splitting the data using scaffold
splitting implemented in DeepChem [10], and consider the Malaria example where active
learning most clearly outperforms random sampling in Figure 5. The underperformance of
active learning is perhaps unsurprising – if the initial screen only consists of one scaffold,
the knowledge that the model has on the other scaffolds would be minimal, i.e. the model
is equally ignorant about all the other scaffolds. As such, randomly sampling the other
scaffolds becomes a reasonable strategy.
17
FIG. 6. Choosing diverse compounds in the initial screen is crucial to successful active learning.
We first randomly split the Malaria dataset into training (80%) and test (20%) sets. We then
scaffold-split the training set to obtain a biased initial set (25% of the total training set), and at
each iteration 2.5% of the training set is given to the model, selected randomly (random sampling)
or based on highest epistemic uncertainty (active learning).
IV. DISCUSSION AND CONCLUSION
We propose a novel method to quantify uncertainty in molecular properties prediction.
We show that our methodology significantly outperforms the baseline on a range of bench-
mark problems, both in terms of model accuracy and in terms of uncertainty estimates. Our
method also overcomes dataset bias by returning a large uncertainty estimate when the test
set is drawn from a different region of chemical space compared to the training set. Moreover,
our methodology can drive an active learning cycle, maximising model performance while
minimising the size of the training set. The key to the success of our method is the com-
bination of semi-supervised learning and Bayesian deep learning. Semi-supervised learning
allows us to learn informative molecular representation in the low data limit. Bayesian deep
learning allows us to estimate aleatoric and epistemic uncertainty in a statistically principled
manner. We exemplified our methodology on regression as it is generally more challenging
than classification, although it can be readily extended to classification problems.
Our observation that the choice of Bayesian inference methodology significantly impacts
the quality of the uncertainty estimate suggests an evident followup that probes the math-
ematical limit of Bayesian inference – i.e. benchmarking approximate inference techniques
against importance sampling of the posterior using Markov Chain Monte Carlo till conver-
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gence, which is computationally expensive but mathematically exact. Moreover, we note
that most approximate inference techniques in the literature have been benchmarked in
terms of RMSE error or log-likelihood [45], rather than explicitly considering the quality of
the uncertainty estimate in a manner relevant for chemoinformatics such as the confidence-
error curve. An open question is the design of appropriate approximate inference techniques
for graph convolutional neural networks that solves the trilemma between computational
cost, model accuracy, and the quality of uncertainty estimate.
Another open question is whether the model has accurately disentangled aleatoric and
epistemic uncertainty. Answering this question would require estimates of the ground truth
aleatoric uncertainty, which is obtainable via repeating the experimental measurement and
reporting the variance. Benchmark datasets which provide accurate experimental uncer-
tainty estimates will be invaluable to advancing the Bayesian methodology.
Finally, our active learning methodology performs well when the initial screen covers
diverse compounds. To successfully perform active learning on a scaffold-biased initial set,
the model needs information on the bioactivity of those unseen scaffolds. We speculate that
strategies such as multitask learning [46, 47], which pools information from other cognate
assays which have explored the unseen scaffolds, will be a fruitful avenue.
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